Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2014

View Archived Issues

AstraZeneca reports progress during second quarter 2014

Bioengineering of T cells to redirect targeting specificity towards infectious fungi

Synthetic Biologics begins clinical program for SYN-004

NIH grant supports Seattle BioMed and collaborators establish new biotechnology resource

Kadimastem to collaborate with Merck Serono in neurodegenerative diseases

Regulus and Biogen Idec establish new microRNA biomarker collaboration in MS

International Stem Cell and Tulane University collaborate on stroke program

Organogenesis wins U.S. Department of Veteran Affairs contract for Apligraf

AmorChem, Universite Laval and CHU de Quebec collaborate for Friedreich's ataxia

Ono Pharmaceutical updates progress of first quarter of fiscal 2014

Oraya Therapeutics awarded grant for gold nanoparticles

Concordia Healthcare begins phase III bile duct cancer trial using PDT with Photofrin

4D pharma receives FDA orphan drug designation for second IBD candidate

Sym-004 advances into two new trials

New compounds for malaria disclosed by French group

Merck & Co. discloses novel HCV NS5A inhibitors

New irciniastatin analogues designed for cancer

Roche and Siena Biotech divulge new BACE1 inhibitors

GlaxoSmithKline patents novel Lp-PLA2 inhibitors

Emergent BioSolutions submits BLA to FDA for anthrax immune globulin

ALN-AT3 receives orphan drug designations in the E.U.

Novel serum miRNA panel for early-stage diagnosis of colorectal adenocarcinoma

FDA issues emergency use authorization for EZ1 rRT-PCR Assay to detect Ebola virus

Defyrus and H&P Labs sign agreement for DEF-201

FDA modifies full clinical hold on Tekmira's TKM-Ebola IND

Efforts ramped up to develop Ebola vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...